Evotec is shuttering four sites and cutting 800 positions as part of an escalating two-year reorganization. The German biotech services company has been struggling with leadership turnover and strategic uncertainty since its former CEO departed amid a short-seller attack.
Unlike the AI-driven cuts dominating 2026 headlines, Evotec's restructuring is about fundamental business model viability. The company provides drug discovery services to pharmaceutical companies, and the combination of pricing pressure, site consolidation, and operational inefficiency has forced a deep structural overhaul.